Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2022

08.09.2021 | Gynecologic Oncology

Developing a validated nomogram for predicting ovarian metastasis in endometrial cancer patients: a retrospective research

verfasst von: Xiaodie Liu, Yaohai Wu, Peishu Liu, Xiaolei Zhang

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To explore risk factors and develop a prediction model for ovarian metastasis in endometrial cancer (EC), as well as providing provide a reference for clinical ovarian preservation.

Methods

We conducted a retrospective observational study enrolling 1496 EC patients having received complete staging surgery from Qilu Hospital of Shandong University from 2012 to 2018. These patients were randomly divided into two cohorts: training cohort (n = 1046) and validation cohort (n = 448). A nomogram prediction model was developed based on univariate, least absolute shrinkage and selection operator (Lasso), and multivariate logistic regression. Then, the nomogram model’s performance was evaluated in discrimination, calibration, and clinical utility three aspects.

Results

Parametrium invasion, lymph node metastasis, and oviduct metastasis were finally contained in the nomogram prediction model. The AUC of the model in the training cohort was 0.85 compared with 0.72 in the validation cohort. It also behaved well in calibration and had good clinical utility. With a threshold probability of 20% ~ 80%, the nomogram increased the net benefit by 0 ~ 13.6 per 100 patients than surgery for all patients upon validation.

Conclusions

We develop a nomogram with good performances for predicting ovarian metastasis in EC patients, which may help clinicians identify candidate patients appropriate for ovarian preservation in premenopausal EC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA Cancer J Clin 68(1):7–30PubMed Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA Cancer J Clin 68(1):7–30PubMed
2.
Zurück zum Zitat Lee YC, Lheureux S, Oza AM (2017) Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol 29(1):47–58PubMed Lee YC, Lheureux S, Oza AM (2017) Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol 29(1):47–58PubMed
3.
Zurück zum Zitat Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. J Natl Cancer Inst 110(4):354–361PubMed Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. J Natl Cancer Inst 110(4):354–361PubMed
4.
Zurück zum Zitat Taylan E, Oktay K (2019) Fertility preservation in gynecologic cancers. Gynecol Oncol 155(3):522–529PubMed Taylan E, Oktay K (2019) Fertility preservation in gynecologic cancers. Gynecol Oncol 155(3):522–529PubMed
5.
Zurück zum Zitat Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS et al (2007) Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 109(3):655–662PubMed Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS et al (2007) Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 109(3):655–662PubMed
6.
Zurück zum Zitat de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20(9):1273–1285PubMedPubMedCentral de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20(9):1273–1285PubMedPubMedCentral
7.
Zurück zum Zitat Ignatov T, Eggemann H, Burger E, Ortmann O, Costa SD, Ignatov A (2018) Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival. J Cancer Res Clin Oncol 144(6):1103–1107PubMed Ignatov T, Eggemann H, Burger E, Ortmann O, Costa SD, Ignatov A (2018) Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival. J Cancer Res Clin Oncol 144(6):1103–1107PubMed
8.
Zurück zum Zitat Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I (2005) Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 106(4):693–699PubMed Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I (2005) Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 106(4):693–699PubMed
9.
Zurück zum Zitat AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A et al (2012) Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecol Oncol 125(1):109–113PubMed AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A et al (2012) Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecol Oncol 125(1):109–113PubMed
10.
Zurück zum Zitat Song T, Seong SJ, Bae DS, Suh DH, Kim DY, Lee KH et al (2013) Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study. Gynecol Oncol 131(3):624–628PubMed Song T, Seong SJ, Bae DS, Suh DH, Kim DY, Lee KH et al (2013) Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study. Gynecol Oncol 131(3):624–628PubMed
11.
Zurück zum Zitat Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN et al (2014) Prevention of diseases after menopause. Climacteric 17(5):540–556PubMed Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN et al (2014) Prevention of diseases after menopause. Climacteric 17(5):540–556PubMed
12.
Zurück zum Zitat Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd et al (2009) Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16(1):15–23PubMedPubMedCentral Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd et al (2009) Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16(1):15–23PubMedPubMedCentral
13.
Zurück zum Zitat Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821–828PubMed Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821–828PubMed
14.
Zurück zum Zitat Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM et al (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716PubMedPubMedCentral Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM et al (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716PubMedPubMedCentral
15.
Zurück zum Zitat Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J (2017) Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 27(1):77–84PubMed Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J (2017) Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 27(1):77–84PubMed
16.
Zurück zum Zitat Gonthier C, Trefoux-Bourdet A, Koskas M (2017) Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. Int J Gynecol Cancer 27(3):493–499PubMed Gonthier C, Trefoux-Bourdet A, Koskas M (2017) Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium. Int J Gynecol Cancer 27(3):493–499PubMed
17.
Zurück zum Zitat Jia P, Zhang Y (2017) Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. Oncotarget 8(35):59940–59949PubMedPubMedCentral Jia P, Zhang Y (2017) Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. Oncotarget 8(35):59940–59949PubMedPubMedCentral
18.
Zurück zum Zitat Hou T, Sun Y, Li J, Liu C, Wang Z, Li Y et al (2017) The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching. Comb Chem High Throughput Screening 20(7):647–655 Hou T, Sun Y, Li J, Liu C, Wang Z, Li Y et al (2017) The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching. Comb Chem High Throughput Screening 20(7):647–655
19.
Zurück zum Zitat Shin W, Park SY, Kang S, Lim MC, Seo SS (2020) The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis. J Ovarian Res 13(1):97PubMedPubMedCentral Shin W, Park SY, Kang S, Lim MC, Seo SS (2020) The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis. J Ovarian Res 13(1):97PubMedPubMedCentral
20.
Zurück zum Zitat Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y et al (2016) Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. Obstet Gynecol 127(1):101–108PubMedPubMedCentral Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y et al (2016) Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. Obstet Gynecol 127(1):101–108PubMedPubMedCentral
21.
Zurück zum Zitat GilaniModaress M, Cheraghi F, Zamani N (2011) Ovarian metastasis in endometriod type endometrial cancer. Int J Fertility Sterility 5(3):148–151 GilaniModaress M, Cheraghi F, Zamani N (2011) Ovarian metastasis in endometriod type endometrial cancer. Int J Fertility Sterility 5(3):148–151
22.
Zurück zum Zitat Li J, Zhu Q, Yang B, Ning C, Liu X, Luo X et al (2018) Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients. Eur J Obstet Gynecol Reprod Biol 222:151–154PubMed Li J, Zhu Q, Yang B, Ning C, Liu X, Luo X et al (2018) Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients. Eur J Obstet Gynecol Reprod Biol 222:151–154PubMed
23.
Zurück zum Zitat Gemer O, Bergman M, Segal S (2004) Ovarian metastasis in women with clinical stage I endometrial carcinoma. Acta Obstet Gynecol Scand 83(2):208–210PubMed Gemer O, Bergman M, Segal S (2004) Ovarian metastasis in women with clinical stage I endometrial carcinoma. Acta Obstet Gynecol Scand 83(2):208–210PubMed
24.
Zurück zum Zitat Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. JCO 26(8):1364–1370 Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. JCO 26(8):1364–1370
26.
Zurück zum Zitat Amant F, Mirza MR, Koskas M, Creutzberg CL (2018) Cancer of the corpus uteri. Int J Gynaecol Obstet 143(Suppl 2):37–50PubMed Amant F, Mirza MR, Koskas M, Creutzberg CL (2018) Cancer of the corpus uteri. Int J Gynaecol Obstet 143(Suppl 2):37–50PubMed
27.
Zurück zum Zitat Jundt G (2018) Updates to the WHO classification of bone tumours. Pathologe 39(2):107–116PubMed Jundt G (2018) Updates to the WHO classification of bone tumours. Pathologe 39(2):107–116PubMed
28.
Zurück zum Zitat Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB et al (2014) Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133(2):216–220PubMed Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB et al (2014) Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133(2):216–220PubMed
29.
Zurück zum Zitat Park SY (2018) Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg 155(4):1793PubMed Park SY (2018) Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg 155(4):1793PubMed
30.
Zurück zum Zitat Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26(6):565–574PubMedPubMedCentral Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26(6):565–574PubMedPubMedCentral
31.
Zurück zum Zitat Campbell W, Ganna A, Ingelsson E, Janssens AC (2016) Prediction impact curve is a new measure integrating intervention effects in the evaluation of risk models. J Clin Epidemiol 69:89–95PubMed Campbell W, Ganna A, Ingelsson E, Janssens AC (2016) Prediction impact curve is a new measure integrating intervention effects in the evaluation of risk models. J Clin Epidemiol 69:89–95PubMed
32.
Zurück zum Zitat Wang J, Li XM (2016) Meta-analysis of prognosis of ovarian preserving in young patients with early endometrial cancer. Zhonghua Fu Chan Ke Za Zhi 51(8):602–607PubMed Wang J, Li XM (2016) Meta-analysis of prognosis of ovarian preserving in young patients with early endometrial cancer. Zhonghua Fu Chan Ke Za Zhi 51(8):602–607PubMed
33.
Zurück zum Zitat Li L, Wu L, Zhang R, Zhang G, Li N, Li X et al (2014) Clinical analysis of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger. Zhonghua Fu Chan Ke Za Zhi 49(4):260–264PubMed Li L, Wu L, Zhang R, Zhang G, Li N, Li X et al (2014) Clinical analysis of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger. Zhonghua Fu Chan Ke Za Zhi 49(4):260–264PubMed
34.
Zurück zum Zitat van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD (1996) Age at menopause as a risk factor for cardiovascular mortality. Lancet 347(9003):714–718PubMed van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD (1996) Age at menopause as a risk factor for cardiovascular mortality. Lancet 347(9003):714–718PubMed
35.
Zurück zum Zitat Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316(18):1105–1110PubMed Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316(18):1105–1110PubMed
36.
Zurück zum Zitat Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD et al (2016) Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. Obstet Gynecol 128(4):761–770PubMedPubMedCentral Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD et al (2016) Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. Obstet Gynecol 128(4):761–770PubMedPubMedCentral
37.
Zurück zum Zitat Lau HY, Twu NF, Yen MS, Tsai HW, Wang PH, Chuang CM et al (2014) Impact of ovarian preservation in women with endometrial cancer. JCMA 77(7):379–384PubMed Lau HY, Twu NF, Yen MS, Tsai HW, Wang PH, Chuang CM et al (2014) Impact of ovarian preservation in women with endometrial cancer. JCMA 77(7):379–384PubMed
38.
Zurück zum Zitat Sun C, Chen G, Yang Z, Jiang J, Yang X, Li N et al (2013) Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril 100(3):782–787PubMed Sun C, Chen G, Yang Z, Jiang J, Yang X, Li N et al (2013) Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril 100(3):782–787PubMed
39.
Zurück zum Zitat Lau HY, Chen MY, Ke YM, Chen JR, Chen IH, Liou WS et al (2015) Outcome of ovarian preservation during surgical treatment for endometrial cancer: a Taiwanese Gynecologic Oncology Group study. Taiwan J Obstet Gynecol 54(5):532–536PubMed Lau HY, Chen MY, Ke YM, Chen JR, Chen IH, Liou WS et al (2015) Outcome of ovarian preservation during surgical treatment for endometrial cancer: a Taiwanese Gynecologic Oncology Group study. Taiwan J Obstet Gynecol 54(5):532–536PubMed
40.
Zurück zum Zitat Casey L, Singh N (2020) Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances. Histopathology 76(1):37–51PubMed Casey L, Singh N (2020) Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances. Histopathology 76(1):37–51PubMed
41.
Zurück zum Zitat Akel RA, Guo XM, Moravek MB, Confino R, Smith KN, Lawson AK et al (2020) Ovarian stimulation is safe and effective for patients with gynecologic cancer. J Adolesc Young Adult Oncol 9(3):367–374PubMedPubMedCentral Akel RA, Guo XM, Moravek MB, Confino R, Smith KN, Lawson AK et al (2020) Ovarian stimulation is safe and effective for patients with gynecologic cancer. J Adolesc Young Adult Oncol 9(3):367–374PubMedPubMedCentral
42.
Zurück zum Zitat Kinjyo Y, Kudaka W, Ooyama T, Inamine M, Nagai Y, Aoki Y (2015) Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstet Gynecol Scand 94(4):430–434PubMed Kinjyo Y, Kudaka W, Ooyama T, Inamine M, Nagai Y, Aoki Y (2015) Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstet Gynecol Scand 94(4):430–434PubMed
43.
Zurück zum Zitat Smith D, Stewart CJR, Clarke EM, Lose F, Davies C, Armes J et al (2018) ER and PR expression and survival after endometrial cancer. Gynecol Oncol 148(2):258–266PubMed Smith D, Stewart CJR, Clarke EM, Lose F, Davies C, Armes J et al (2018) ER and PR expression and survival after endometrial cancer. Gynecol Oncol 148(2):258–266PubMed
44.
Zurück zum Zitat Ballester M, Canlorbe G, Cortez A, Gonin J, Laas E, Bendifallah S et al (2013) Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecol Oncol 130(3):457–462PubMed Ballester M, Canlorbe G, Cortez A, Gonin J, Laas E, Bendifallah S et al (2013) Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecol Oncol 130(3):457–462PubMed
Metadaten
Titel
Developing a validated nomogram for predicting ovarian metastasis in endometrial cancer patients: a retrospective research
verfasst von
Xiaodie Liu
Yaohai Wu
Peishu Liu
Xiaolei Zhang
Publikationsdatum
08.09.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2022
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-021-06214-4

Weitere Artikel der Ausgabe 3/2022

Archives of Gynecology and Obstetrics 3/2022 Zur Ausgabe

Gynecologic Endocrinology and Reproductive Medicine

Blastocyst versus cleavage transfers: who benefits?

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.